FDA Approves Vyvgart for Adults With Most Common Form of gMG

FDA Approves Vyvgart for Adults With Most Common Form of gMG

314648

FDA Approves Vyvgart for Adults With Most Common Form of gMG

Vyvgart (efgartigimod) has been approved by the U.S. Food and Drug Administration (FDA) to treat adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive, the therapy’s developer, Argenx, announced. According to Argenx, this patient group represents about 85% of all with generalized MG. “Today is the start of a new era for argenx and the gMG community as we honor our commitment to bring forward an innovative treatment option for people living with…

You must be logged in to read/download the full post.